Pulmatrix Appoints Respiratory and Allergy Expert, Michael Yeadon, PhD, to Scientific Advisory Board

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced today that it has added Michael Yeadon, PhD, to the company’s Scientific Advisory Board to offer expertise as the company accelerates its research and clinical programs. Dr. Yeadon will have a dual role in advising Pulmatrix. First, he will be an integral member of the company’s Scientific Advisory Board (SAB), supporting the preclinical and clinical advancements of the company’s novel iCALM™ platform in COPD, asthma, and CF, as well as the company’s novel dry powder iSPERSE™ platform. In addition, Dr. Yeadon will serve as an executive advisor and provide regular strategic counsel to Pulmatrix’s senior management team, Board of Directors and investors.